Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
1. An isolated amino-terminal truncated human tryptophanyl-tRNA synthetase polypeptide capable of regulating angiogenesis comprising a carboxyl-terminal portion of SEQ ID NO: 10, which includes a Rossmann fold nucleotide binding domain.
2. The isolated polypeptide of claim 1 , wherein the truncated polypeptide has a size of 41 kilodaltons.
3. The isolated polypeptide of claim 1 , wherein the polypeptide is angiogenic.
4. The isolated polypeptide of claim 1 , wherein the polypeptide is angiostatic.
5. The isolated polypeptide of claim 1 wherein the polypeptide is a member of the group consisting of
a polypeptide consisting of amino acid residues 48–471 of SEQ ID NO:10;
a polypeptide consisting of amino acid residues 71–471 of SEQ ID NO:10; and
a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO:10 with polymorphonuclear leucocyte elastase.
6. An isolated polypeptide which is an amino-terminal truncated human tryptophanyl-tRNA synthetase polypeptide having chemokine activity comprising a carboxyl-terminal portion of SEQ ID NO: 10, which includes a Rossmann fold nucleotide binding domain.
7. The isolated polypeptide of claim 6 , wherein the polypeptide has angiogenic activity.
8. The isolated polypeptide of claim 7 , wherein the angiogenic activity is at least two-fold greater than control levels.
9. The isolated polypeptide of claim 6 , wherein the polypeptide has angiostatic activity.
10. The isolated polypeptide having angiostatic activity of claim 9 , wherein the polypeptide suppresses at least ten percent of angiogenic activity.
11. The isolated polypeptide having angiostatic activity of claim 9 , wherein the polypeptide suppresses at least ninety percent of angiogenic activity.
12. A composition comprising the isolated polypeptide of claim 1 and a pharmaceutically suitable excipient.
13. A composition comprising the isolated polypeptide of claim 5 and a pharmaceutically suitable excipient.
14. A composition comprising the isolated polypeptide of claim 6 and a pharmaceutically suitable excipient.